Evidence, not hype
Microdosing GLP-1, measured.
Every low-dose provider’s published price on one screen, a review of each, and what the research does and doesn’t show. Off-label and unproven — we say so throughout.
Editor's #1 pick
$79–$129/mo flatCoreAge Rx
Doctor-reviewed low-dose GLP-1 protocols with flat pricing and built-in human support. It is the one provider here that prices the low dose as a product in its own right, with no membership or lab fee underneath it. We rank on provider value, never on a promise of results.
Some of the providers we rank pay us a commission if you start through our link, at no extra cost to you. Every provider on the ranking gets the same write-up and the same button. See our disclosure.
Also worth comparing
- Visit site
Found
From $99/mo (compounded, varies) · Established, physician-designed weight-care telehealth with a broad formulary, real coaching, and a new GLP-1 microdosing program.
- Visit site
Gala Health
$149/mo micro tirz (yearly subscription) · Both molecules in all 50 states with a microdose tier priced below the standard one — on a yearly subscription.
Microdosing is off-label and unproven — decide with a clinician.
The research
All 61 →Microdosing GLP-1: What the Evidence Actually Shows
An honest, citation-backed look at GLP-1 microdosing — an unstudied, off-label practice. What the trials prove, and why less dose means less effect.
Does Microdosing GLP-1 Actually Work?
Does microdosing GLP-1 work? Honestly: no trial has tested it. Here's what dose-response data and standard-dose trials imply, and why anecdotes aren't evidence.
GLP-1 Dose-Response: Why Lower Doses Do Less
The dose-response data are clear: lower GLP-1 doses do less. The semaglutide dose-finding figures, the tirzepatide tiers, and why exposure matters.
Every conclusion traces to primary research or official labeling, including null results. Some providers on the ranking pay us a commission, at no extra cost to you, and we say so on the ranking itself. Read how we research and rank in our editorial policy.